Once-weekly insulin icodec is a potential game-changer in T2D management, and it can be used instead of once-daily long-acting regimens without compromising the overall efficacy and safety profile of basal insulin therapy in T2D patients. This evidence concerns the gene INS and type 2 diabetes mellitus.